Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 double-blind randomized study of RO7049665 in autoimmune hepatitis
2020-003990-23Phase 2Terminated
- Sponsor
- Roche
- Start
- Feb 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of melredableukin alfa in autoimmune hepatitis (AIH), sponsored by Roche. Primary endpoint: Time to relapse from randomization. Started Feb 2021; status: terminated.
02
Drugs
melredableukin alfa
03
Conditions
autoimmune hepatitis (AIH)
Beyond the preview
Go deeper on 2020-003990-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003990-23.